UNLOCKING POTENTIAL IN LIFE SCIENCES: COLLABORATIVE RESEARCH BETWEEN ACADEMIA AND INDUSTRY IN EUROPE

8 October 2024, Milan

9:15 a.m. – 1.00 p.m.

c/o Fondazione Human Technopole Auditorium – Viale Rita Levi Montalcini, 1

8.45 – 9.15 a.m. | **Welcome and registration**

9.15 – 9.30 a.m. | **Welcome address and scope of the event**

Gianmario Verona – President, Fondazione Human Technopole

9.30 – 9.45 a.m. | **Analysis by The European House – Ambrosetti**

Corrado Panzeri – Partner & Head of InnoTech Hub, The European House – Ambrosetti

9.45 – 10.05 a.m. | **Speaker 1**

Bert Klebl – Managing Director and Chief Scientific Officer, Lead Discovery Centre

10.05 – 10.25 a.m. | **Speaker 2**

Alessandro Curioni – IBM fellow, VP Europe and Africa and Director, IBM Research Zurich

10.25 – 10.45 a.m. | **Speaker 3**

David Hulcoop[1] - Executive Director, Open Targets

10.45 – 11.00 p.m. | **Q&A**

11.00 – 11.30 a.m. | **Coffee break**

11.30 – 12.30 a.m. | **Roundtable Discussion**

Daniela Bellomo - Director Business Development and Technology Transfer Division, Ospedale San Raffaele

Fabrizio Conicella – Head of Open Innovation & Competence, Chiesi Farmaceutici

Sergio Dompé – President, Dompé Farmaceutici

Fabrizio Grillo – President, Federated Innovation @MIND

Marica Nobile – Director, Federchimica Assobiotec

Francesca Pasinelli – Board Member, Fondazione Telethon

Maria Cristina Porta – General Manager, ENEA Tech e Biomedical

Marino Zerial – Director, Fondazione Human Technopole

Coordinated by: **Fabio Terragni**, Member of the Management Committee delegate for technology

[1] Video conference.

transfer, Fondazione Human Technopole

12.30 – 13.00 p.m. | Q&A and closing remarks

13.00 – 2.30 p.m. | Networking lunch

Concept

The process of technology transfer in the Life Sciences aims to advance early scientific inventions and discoveries to the next generation of diagnostics, therapies, services, and enterprises. Because of its intrinsic attitude to risk, hypothesis-driven research, and data sharing, academia produces a large amount of highly valuable discoveries and inventions that, regrettably, do not always translate into therapies and products beneficial for society. Indeed, the journey from academic research to patients requires competencies, know-how, and access to considerable scientific, human, and economic resources. Academia spin-offs and start-ups often lack the resources and know-how to tackle these challenges. On the other hand, the industry has been thriving in delivering breakthrough therapies and diagnostic tools to patients while not being as effective as academia in producing breakthrough scientific discoveries. Collaboration between academia and industry is essential to unlock the full potential of both worlds, and Europe hosts several examples of such collaborations.

With this in mind, we would like to gather some of the key players in the Italian Life Science ecosystem to discuss such European examples and join efforts to build a model for Italy.